Rob Hartman has over 10 years of life sciences and commercialization experience. He is currently the Director of Translational Science at UPMC Enterprises where he leads investment strategy and operations for immunotherapy-related startups. Prior to working with UPMC, he was an innovation and commercialization consultant within the University of Pittsburgh where he received his bachelor’s, master’s, and doctorate degrees in bioengineering. In addition to his professional experience, he is an invited and substitute lecturer at the University of Pittsburgh in applied bioethics for undergraduate and graduate bioengineering students.